Semaglutide (Ozempic, Wegovy), a GLP-1 agonist drug used to treat diabetes and obesity, may also help people with fatty liver disease, called metabolic dysfunction–associated steatotic liver disease (MASLD). About 20% of people with MASLD develop liver inflammation known as metabolic dysfunction–associated steatohepatitis (MASH). MASH can lead to scarring of the liver and cirrhosis, and it is one of the most common reasons for liver transplants.